Life changing impact: Rapid reduction in itch

Reduction in itch

Rapid itch reduction
after the 1st dose with Xolair® 300 mg*1
 

71%

reduction in itch
with Xolair® 300 mg vs
baseline at 12 weeks*1,2
 

44%

of patients were itch-
and hive-free with Xolair®
300 mg at 12 weeks*1
 

Simple dosing schedule

Xolair® is administered by
subcutaneous injection, using a pre-filled syringe‡3

Find out more

Well tolerated

Xolair® was well tolerated
in over 700 patients
in the CSU phase III
clinical program3

Find out more

Model is a hypothetical patient profile, for illustrative purposes only

*Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients

†Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo.

‡Xolair® is also available as a lyophilized formulation

References: 1. Maurer M, et al. N Engl J Med 2013;368:924-935. 2. Casale T, et al. Allergy 2014;69(Suppl 99). Abstr 1662. 3. Xolair® Summary of Product Characteristics 2016.

NP4 code: GLDEIM/IGE025E/0181

Terms of use - Privacy policy - About cookies - Cookie Settings - This site is intended for a global audience.

© 2017 Novartis Pharma